Nicolas COLLONGUES
University Hospital, Strasbourg, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nicolas COLLONGUES as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:40 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06663189 · Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)University Hospital, Strasbourg, France · not yet recruiting · Relapsing-remitting Multiple Sclerosis (RRMS) · principal investigator
- Ph2NCT02600286 · Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1AUniversity Hospital, Strasbourg, France · terminated · CMT1A · principal investigator
- N/ANCT01498211 · Normative Data of Intra-epidermal Nerve Fiber DensityUniversity Hospital, Strasbourg, France · completed · Healthy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:40 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.PLoS One · 201724 citationsRCR 1.0
- [Reduced emotional reactivity to negative stimuli in multiple sclerosis, preliminary results].Rev Neurol (Paris) · 201117 citationsRCR 0.7
- Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months.Clin Neuropharmacol · 201617 citationsRCR 0.9